Aim: To examine whether sodium-glucose co-transporter-2 (SGLT2) inhibitors are associated with a higher risk of lower-extremity amputation than dipeptidyl-peptidase-4 (DPP-4) inhibitors and sulphonylureas.
[HR] 1.97, 95% confidence interval [CI] 1.41-2.75), primarily of the toe or forefoot, among patients randomized to canagliflozin, with median follow-up of 126 weeks. 5 This represents an important finding given that T2DM is the leading cause of non-traumatic lowerextremity amputations (LEAs). 8 In response, the US Food and Drug
Administration issued a bulletin regarding amputation risk in May 2016 9 and a drug-labelling change in July 2017. 10 Recently, several observational studies have sought to corroborate this finding in broader populations, with mixed conclusions. [11] [12] [13] [14] [15] [16] To address the variation in observed risk of amputation with SGLT2 inhibitors, we implemented an active comparator new-user (ACNU) study 17 to estimate and compare the risk of LEA between patients initiating SGLT2 inhibitors and patients initiating two secondline GLDs, dipeptidyl peptidase-4 (DPP-4) inhibitors and sulphonylureas (SUs), which are prescribed as alternatives to SGLT2 inhibitors.
Specifically, we explored how selection of different analytical populations and comparators impacted the risk estimates of LEA with SGLT2
inhibitors, and how such choices may have contributed to differences in published findings in this domain.
| METHODS

| Data source
We conducted a cohort study using the Truven Analytics' IBM ® Watson Health MarketScan ® Commercial Claims and Encounters (CCAE)
Database from 2013 to 2015. MarketScan data contain inpatient, outpatient, and pharmaceutical claims and encounters data linked with demographic and enrolment information from~350 insurance payers in the United States. 18 This database is representative of the US population with employer-based insurance and offers longitudinal followup of patients while working for the same employer. 19 The study was determined to be exempt from full institutional review board review by the University of North Carolina at Chapel Hill. The study protocol was registered with the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) on October 23, 2017 (EU PAS Register Number 21368, http://www.encepp.eu/encepp/ viewResource.htm?id=25456).
| Eligible population
The base population consisted of all MarketScan beneficiaries, aged 18 to 64 years, with at least one prescription dispensing claim for an SGLT2 inhibitor, a DPP-4 inhibitor or an SU between March 1, 2013 and September 30, 2015 . To ensure new use of either comparator drug, we required patients to have ≥12 months of continuous MarketScan enrolment prior to the first eligible prescription dispensing claim, during which no prescription for any of the study drug classes could be observed (washout period).
| Exposure definition
Exposure to an SGLT2 inhibitor, a DPP-4 inhibitor or an SU drug (Table S1 ) was defined by at least two same-class drug prescription dispensing claims observed within a predefined window.
This "prescription window" was calculated as the first prescription's recorded days' supply, plus a 30-day grace period. By requiring a second prescription and using that prescription date as the index date, we restricted the analysis to a cohort who we were reasonably confident were taking the cohort drug. Patients were excluded if they:
(a) received a prescription for either study drug prior to index date;
(b) switched to the comparator drug between the first and second prescriptions; (c) received both study drugs on the index date; or (d) received an empagliflozin-linagliptin combination drug on the index date ( Figure S1 ).
| Outcome definitions
The primary outcome of LEA was defined using a combination of
International Classification of Diseases, Ninth Revision, Clinical Modification and Common Procedural Terminology procedure codes.
Patients who experienced LEA between the first and second prescriptions were included in the analysis, with those events captured in the baseline amputation history. Secondary outcomes included other diabetes-related conditions and procedures (tissue and bone debridement, peripheral vascular disease, and diabetic foot ulcer) commonly considered to be direct precursors or alternatives to LEA. Codes for all outcome definitions were informed through prior literature [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] and clinical guidance (Table S2) . For secondary analyses, we excluded patients with baseline history of any outcome.
| Follow-up
The primary analysis was performed in an "as-treated" fashion ( Figure S2 ). Follow-up began at the index date (date of second prescription) and ended when an individual experienced either an outcome of interest or a censoring event (treatment discontinuation, switch or augmentation; disenrolment; or September 30, 2015), whichever came first. Secondary outcome analyses additionally censored patients if LEA was observed prior to occurrence of a secondary outcome.
| Confounding control
We used propensity scores to control for measured confounding. We incorporated covariate groupings for patient demographics, diabetesrelated comorbidities, general health comorbidities, medication use history (including prior use of other GLDs), and measures of healthcare system use in the propensity-score model, measured in the year prior to cohort entry (Table 1) . We also applied the adjusted Diabetes
Complication Severity Index (aDCSI) 31, 32 as a proxy to control for diabetes disease severity.
| Statistical analysis
We estimated propensity scores using multivariable logistic regression to model each patient's predicted probability of receiving an SGLT2
inhibitor, conditional on his or her baseline covariates. We then weighted comparator cohorts by the propensity-score odds
to standardize the distribution of measured covariates to the SGLT2 inhibitor cohorts, and estimated the average treatment effect in those treated. 33 The aim of this approach was to address the question, "Would LEA incidence have changed had all SGLT2
inhibitor initiators instead initiated a comparator drug?". Covariate balance was assessed using the standardized mean difference. 34 For all outcomes, we estimated crude incidence rates (IRs) using
Poisson regression, and crude and adjusted HR (aHR) and 95% CIs using weighted Cox proportional hazards models. We used weighted
Kaplan-Meier methods to estimate the cumulative incidence of LEA, Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blockers; COPD, chronic obstructive pulmonary disease; DCSI, diabetes complication severity index; DPP-4 inhibitor, dipeptidyl peptidase-4 inhibitors; GLP-1, glucagon-like peptide-1; HbA1c, glycated haemoglobin; LEA, lower-extremity amputation; SGLT2, sodium-glucose co-transporter-2; SU, sulphonylurea. a Weighted by standardizing the comparator drug initiators to the population of SGLT2 inhibitor initiators, using the propensity-score odds (PS/(1-PS)), to estimate the treatment effect in those treated. b All baseline characteristics measured in the 1 year (365 days) prior to date of cohort drug initiation.
as well as risk differences and 95% CIs in the 1 to 30, 31 to 90, 91 to 180, and ≥180 days after drug initiation in each study cohort. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina).
| Sensitivity and subgroup analyses
We conducted multiple sensitivity analyses. First, we re-analysed the data using an intention-to-treat (ITT) follow-up approach for up to 1 year, whereby patients were censored only for disenrolment or at the administrative study end date. Second, similarly to previous studies, [11] [12] [13] [14] we performed an analysis requiring only a single prescription claim to be considered exposed to a study drug. Third, to replicate comparator choices in previous studies, we conducted an analysis using any non-metformin, non-SGLT2 inhibitor GLD (SUs, thiazolidinediones, DPP-4 inhibitors, glucagon-like peptide-1 receptor agonists, and insulins) as the comparator group, excluding all patients with baseline use of these agents. Fourth, because LEA risk was specifically noted in the CANVAS programme, we repeated the analysis, restricting it to canagliflozin users.
To assess the impact of various design specifications, we repeated the analyses using 15-, 60-, and 90-day grace periods; 30-, 60-, 90-, and 180-day induction periods; 30-, 60-, 90-, and 180-day latency periods; and a 6-month washout period. We specified a range of induction and latency periods a priori to determine possible durations of time required for treatment initiation to contribute to LEA occurrence; both periods were extended to 6 months to reflect CANVAS results that reported emerging amputation risk by 6 months of followup. We additionally repeated the analysis with 1%, 2.5% and 5%
asymmetric trimming of the propensity score distribution. 35 The CANVAS programme reported a particularly elevated risk of 3 | RESULTS
| Eligible cohort
We identified a total of 328 150 eligible users of at least one study accounted for 69% to 70%, 22% to 23%, and 7% to 8% of SGLT2 inhibitor use, respectively ( Age and gender distributions were similar across cohorts (Table 1 ). Prior to standardized mortality ratio (SMR) weighting, we observed imbalances in several baseline comorbidities, including diabetic nephropathy, neuropathy, hypertension, dyslipidaemia, ischaemic heart disease, and baseline use of angiotensin-receptor blockers, statins and metformin; baseline imbalances were generally more pronounced in the SGLT2 inhibitor versus SU comparison. All measured covariates were balanced after SMR weighting ( Figure S4 ).
| Primary and secondary outcomes
In the as-treated analysis (Table 2) we observed modest to no increases in LEA hazard (Table S4) , with HR estimates ranging from 0.96 to 1.22, and all 95% CIs containing the null.
| Sensitivity and subgroup analyses
Results were consistent across a number of sensitivity analyses (Figure 2, Tables S5 and S6 ). We observed a downward trend in HR estimates for ITT analysis, when requiring only one prescription to define exposure, when using longer grace periods, latency, and induction periods, and when greater trimming was performed.
In the SU comparison, HR estimates increased when using 60-and 90-day induction periods, although estimates remained nonsignifi- 
| DISCUSSION
In this large, ACNU cohort study among commercially insured US Abbreviations: AT, as-treated; CI, confidence interval; DPP-4, dipeptidyl peptidase-4; HR, hazard ratio; IQR, interquartile range; ITT, intention-to-treat; PS, propensity score; SGLT2 inhibitor, sodium-glucose cotransporter-2; SU, sulphonylurea. a Follow-up in ITT analyses was capped at 1 year following the index date. b We observed 51, 59 and 102 lower-extremity amputation events between the first and second prescription fills in the DPP-4 inhibitor, SU and non-SGLT2 inhibitor comparisons, respectively. These patients were not excluded from the primary analysis, but were considered as prior amputations for the assessment of subgroup effects for patients with and without prior amputation history. These amputations were re-introduced as analysis endpoints for the sensitivity analysis where we include patients with at least 1 prescription fill.
new users of all non-SGLT2 inhibitor GLDs. 11, 12 Using as-treated anal- . We attribute these differences to our simultaneous inclusion of insulin (typically a marker of more severe diabetes and higher amputation risk) and exclusion of metformin (often prescribed to patients with less severe diabetes and lower amputation risk) in the non-SGLT2 inhibitor comparator group, which mirrors a commonly used comparator in previous studies. 11, 12, 15 Because the potential mechanisms behind SGLT2 inhibitor and amputation risk remain undetermined -current hypotheses relate to volume depletion and reduced tissue perfusion 11 -we assert that the heterogeneity of findings results primarily from differences in study design decisions. We show that inference regarding comparative LEA risk changes meaningfully when different active comparators (DPP-4 inhibitor vs. SU vs. non-metformin, non-SGLT2 inhibitor GLDs) are employed. We also highlight the important differences between patients prescribed these drugs in practice, which is underscored by the crude baseline differences observed between SGLT2 inhibitor and SU initiators (Table 1) , and between SGLT2 inhibitor and non-metformin, non-SGLT2 inhibitor initiators (Table S7) . Sulphonylureas, for example, while often categorized as a second-line GLD in current diabetes pharmacotherapy guidelines, may not be an ideal analytical alternative to SGLT2 inhibitors because they are less costly and may be more frequently prescribed to patients with lower socio-economic status and healthcare system access. [38] [39] [40] Furthermore, often in restrictive, protocol-driven health systems, approaches are adopted that spare the use of more recent diabetes therapies, such as SGLT2
inhibitors, until after SU treatment has failed. This has previously been used as a first-line therapy as an alternative to metformin. 41, 42 Crude imbalances between SGLT2 inhibitor and non-metformin, non-SGLT2 inhibitor initiators were even more severe (Table S7) Other study design decisions have also contributed to the heterogeneous results of studies conducted in the MarketScan CCAE (Table 3) . First, the present study, which is the first on this topic to define diabetes drug exposure using at least two prescriptions, shows that analyses defining exposure with only one prescription claim tend to yield reduced HR estimates. Second, we showed that Subgroup analyses adjusted for age, sex, baseline neuropathy, baseline peripheral vascular disease, baseline congestive heart failure, baseline chronic kidney disease, baseline ischaemic heart disease, and baseline metformin use 12 Third, analyses using ITT follow-up typically yielded HR estimates closer to the null than those using as-treated approaches, which may have contributed to the observed differences between Yuan et al 11 and Ryan et al, 12 versus Chang et al, 13 Adimadhyam et al, 14 and the present study. Fourth, our subgroup analyses showed that excluding patients with prior amputation and prior CKD reduced HR estimates, whereas excluding patients with baseline insulin use increased HR estimates.
Finally, differences in propensity-score methods and confounder sets can affect the extent to which confounding by indication and diabetes severity is controlled. Kaiser et al 43 have previously shown that potential for residual confounding can vary substantially depending on the outcome under study. Given that studies typically define a single set of confounders, one implication is that confounding control may be more complete in studies that apply these confounders to assess amputation risk alone, 11, 13, 14 versus those that use the same confounders to assess both beneficial and adverse outcomes 5, 15, 16 or to assess multiple adverse outcomes with different mechanisms. 37 In the present study, we aimed to minimize residual confounding by including confounders specific to amputation risk, and prespecified secondary outcomes that we believe share a similar mechanism to amputation risk.
Ultimately, authors should justify study design choices to reflect We then performed a number of sensitivity and subgroup analyses to test the robustness of our primary analysis to different study design choices and specifications, and to quantify the impacts of excluding and stratifying by prior comorbidity and GLD use histories. As analytical approaches continue to evolve around questions of LEA risk with SGLT2 inhibitor use, our understanding of SGLT2 inhibitor effectiveness and safety will continue to deepen.
The present study had several strengths. First, the ACNU study design helps to address issues related to confounding by indication by comparing patients treated with similar second-line T2DM therapies, and provides additional control for other unmeasured confounders and for various time-related biases. 17 Second, propensityscore weighting adequately controlled for remaining measured baseline confounding, as shown in Table 1 . We controlled for baseline use of other oral GLDs, including metformin and insulin, which
were not controlled for in several previous studies. 11, 13 Third, by restricting to patients with at least two prescriptions in close proximity, we gain confidence that patients are actually taking the study drugs. The commonly used approach of defining exposure through a single prescription claim alone can include patients who are not actually on therapy, as prescription dispensing claims do not necessarily reflect whether patients actually take the study drugs after filling the prescription. In our analysis, >30% of patients with one study drug prescription did not fill a second prescription within the allotted prescription window ( Figure S1 , Tables S5 and S6 ). These patients, who contributed 26% of follow-up time in time-to-event analyses, may represent misclassified "exposed" time. Our results indicate that requiring the second prescription, which has not previously been implemented in similar studies, reduces bias towards the null. 44 Finally, we were able to leverage the size of the MarketScan CCAE database to assess subgroup differences by a number of baseline characteristics. Multiple studies have assessed possible differences in amputation risk by CVD status, but no previous observational studies have, to our knowledge, assessed differences in HR by prior amputation history and baseline metformin use.
Although differences in subgroup analyses were modest and precision of estimates was limited because of low event counts, these analyses can nevertheless offer important insight to aid physician decision-making when weighing clinical alternatives among patients with specific comorbidity and diabetes medication use histories.
The present study also had the limitations characteristic of observational studies using administrative data. First, although the MarketScan CCAE database contains data for patients aged ≥65 years, data for these patients are inconsistently reported in MarketScan owing to the priority of Medicare coverage among such patients. To account for these potentially missing claims data, we limited our analysis to employer-insured patients aged <65 years, for whom we are confident data are relatively complete. Thus, our findings may not be generalizable to older or unemployed populations, which may have different amputation risk. Second, although we restricted the analyses to patients aged ≥18 years as a proxy for patients with T2DM, patients with Type 1 diabetes mellitus (T1DM)
may also be present in the study cohort. However, the treatment patterns assessed in this study are more indicative of T2DM, since oral GLDs are uncommonly prescribed in T1DM. 45 Third, the MarketScan CCAE database does not report patient vital status, which precluded modelling of death as a competing risk. However, we did not expect death to be a major competing risk given the short (<1 year) follow-up in our cohort and relatively low mortality expected among the younger, privately-insured population. Fourth, because canagliflozin has dominated SGLT2 inhibitor use in the United States thus far, we did not have sufficient power to study dapagliflozin and empagliflozin individually, and were unable to determine to what extent the class effect observed in this study extends to dapagliflozin and empagliflozin. 46 However, use of dapagliflozin and empagliflozin continues to grow, and evidence should emerge in the coming years. Finally, we acknowledge the possibility of unmeasured confounding attributable to the observational nature of this study and the lack of data on race/ethnicity and socio-economic status. However, we were able to provide partial control through claims-based definitions of dyslipidaemia, aDCSI, smoking cessation, and chronic obstructive pulmonary disease as proxies for patient body mass index, diabetes severity and duration, and smoking status, respectively.
In conclusion, the present cohort study adds to, and contextual- 
